By Manas Mishra and Trisha Roy (Reuters) - Biogen Inc <BIIB.O> raised its 2020 earnings forecast on Wednesday after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates.The results brightened the mood following a setback in June on a key Tecfidera patent, uncertainty over approval of the company's experimental Alzheimer's disease drug aducanumab and rising competition for its other growth driver Spinraza.